Summary

The Thailand Diabetes Care Devices Market size is estimated at USD 128.94 million in 2024, and is expected to reach USD 175.49 million by 2029, growing at a CAGR of 6.36% during the forecast period (2024-2029).

The healthcare system was significantly disturbed and pressured during each phase of rapid COVID-19 infection. Several countries, notably the Thai government, have introduced home isolation or a home quarantine program to avert healthcare collapse and to ameliorate inadequate healthcare resources. Between July 2021 and October 2021, COVID-19 illness cases in Thailand increased to around 20,000-25,000 cases per day, posing difficulty in the treatment of COVID-19 infection in hospitals. Previous research revealed the viability of a COVID-19 home monitoring program employing telemedicine to reduce the gap in treatment during a healthcare worker shortage in multiple countries2-5. These programs primarily monitored the intensity of symptoms and informed patients to seek additional treatment if necessary. During COVID-19, there was a shortage of hospital capacity, and a home isolation system was set up. Thailand's government introduced diabetes self-management education and support (DSMES) and glycemic management via telemedicine, along with outcomes in home-isolated patients with COVID-19 infection. In AUG 2022, The National Research Council of Thailand (NRCT) introduced a breathalyzer prototype that can detect those infected with Covid-19 with 97% accuracy.

Thailand's government During COVID-19 provided medical supplies, including glucometers, blood glucose test strips, lancets, and urine test strips were donated or purchased using donated funds. The supplies were stocked at a central location and distributed by volunteers, utilizing same-day commercial delivery services. Disposable prefilled insulin pens, both long-acting and short-acting analogs, were chosen instead of insulin vials to reduce administration errors, particularly in insulin-naïve patients. Insulin pens were kept at a medical clinic and distributed in a temperature-controlled container by a same-day delivery service.

Thailand Diabetes Care Devices Market Trends

Management Devices Segment is Having Highest Share in current year

Blood pressure regulation is a critical component of diabetes management. Furthermore, even without high blood pressure, certain blood pressure-lowering medications are frequently recommended for people with diabetes to protect them from kidney and heart-related complications. No scientific evidence links these blood pressure drugs to the likelihood of COVID-19 infection or associated consequences. High blood sugar levels (hyperglycemia) are a symptom of diabetes mellitus, which a lack of insulin hormones can bring on, a problem with insulin secretion, or both. High blood sugar levels can cause essential organs to malfunction, deteriorate, and be destroyed. Both changeable and immutable variables can contribute to an inability to control blood sugar levels. Gender, age, the length of diabetes, microvascular and macrovascular complications, and comorbidities are non-modifiable factors. Behavioral and psychosocial problems, such as poor eating habits, inactivity, obesity, and failure to take prescribed medications as directed by a doctor, as well as stress, sadness, and anxiety, particularly anxiety associated with diabetes, are examples of modifiable factors.

Insulin therapy is the most potent hypoglycaemic medication currently available for diabetes treatment; however, the potency of insulin deteriorates if it is stored under improper conditions. In Thailand, NCDs, including diabetes, account for more than 70% of all deaths. Obesity leads to a more than seven times increase in the risk of developing Type 2 diabetes while being overweight increases the risk by three times.

Through Thailand's government encouragement, the usage of Management Devices increased over the forecast period.

Increasing Diabetes population in Thailand

The World Health Organization (WHO) estimates that in 2022, around 11% of the total health expenditure in Thailand will be allocated to diabetes care, which is comparable to other countries in the region. By 2030, this figure is expected to grow by 41%, effectively doubling the societal burden of diabetes. In Thailand, only 272 endocrinologists (or specialists) are available. In Thailand, three out of five people with diabetes who receive care do not achieve the recommended treatment targets. According to the WHO's report, the world's top five countries suffering from diabetes include Indonesia, China, India, Brazil, and the United States. Thailand is facing an increase in the number of diabetes patients due to changing lifestyles, resulting in the prevalence of obesity. Sedentary lifestyles and unhealthy diets are more common in urban areas of Thailand. The Thai government is attempting to address the threat of diabetes mellitus through programs like 'Thailand Healthy Lifestyle Strategic Plan 2011-2020'. Such programs will help diabetic patients understand the benefits of various diabetes devices available in the market. Diabetes is one of the biggest health issues facing the world today, and its prevalence is steadily rising. According to the World Diabetes Federation, 450 million people worldwide already have diabetes, and 642 million will have it by 2041. Asian nations account for more than 60% of those with diabetes worldwide2. Furthermore, compared to people of other races, Asians may be more prone to having type 2 diabetes and at a higher risk of getting diabetes complications.

The increasing diabetes population and the technological advancements in Indonesia drive the market.

Thailand Diabetes Care Devices Industry Overview

The new technologies in diabetes devices, like continuous glucose monitoring, increased the market for monitoring devices. The mergers and acquisitions between the players, like the acquisition of TypeZero Technologies by Dexcom, are paving the way for automated insulin delivery. The acquisition has sent Dexcom ahead in the race to create an artificial pancreas system rather than merely offering a boost to the continuous glucose monitoring devices market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

ページTOPに戻る

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Industry Attractiveness - Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 Monitoring Devices
5.1.1 Self-monitoring Blood Glucose Devices
5.1.1.1 Glucometer Devices
5.1.1.2 Test Strips
5.1.1.3 Lancets
5.1.2 Continuous Blood Glucose Monitoring
5.1.2.1 Sensors
5.1.2.2 Durables
5.2 Management Devices
5.2.1 Insulin Pump
5.2.1.1 Insulin Pump Device
5.2.1.2 Insulin Pump Reservoir
5.2.1.3 Infusion Set
5.2.2 Insulin Syringes
5.2.3 Insulin Cartridges
5.2.4 Disposable Pens

6 MARKET INDICATORS
6.1 Type-1 Diabetes population
6.2 Type-2 Diabetes population

7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Becton and Dickenson
7.1.2 Medtronic
7.1.3 Insulet
7.1.4 Tandem
7.1.5 Ypsomed
7.1.6 Novo Nordisk
7.1.7 Sanofi
7.1.8 Eli Lilly
7.1.9 Abbottt
7.1.10 Roche
7.1.11 Lifescan (Johnson &Johnson)
7.1.12 Dexcom
7.2 Company Share Analysis

8 MARKET OPPORTUNITIES AND FUTURE TRENDS